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The effect of PlySs1 and PlySs2 on clinical symptoms and transmission of Streptococcus suis serotype 9 in weaned pigs

Abstract
Streptococcus suis is an important porcine pathogen worldwide. The conventional treatment of S. suis implies the use of antibiotics, but current associations between the use of antibiotics in pig breeding and the development of antibiotic resistant strains of bacteria ask for research on alternatives for antibiotics.
PlySs1 and PlySs2 are enzymes derived from bacteriophages, which are capable of killing bacteria by lysing the bacterial cell wall. The effect of PlySs1 and PlySs2 was investigated in a group of caesarean derived, colostrum deprived (CDCD) piglets. The aim of this research was to determine the effect of PlySs1 and PlySs2 on the transmission of Streptococcus suis serotype 9 between pigs, and the effect on the development of clinical symptoms caused by Streptococcus suis serotype 9 in pigs.





Streptococcus suis is an important porcine pathogen worldwide. It can cause various pathological conditions, such as (poly)arthritis, meningitis, pneumonia and septicemia, and therefore it counts for many economical losses in the swine industry. Worldwide, 35 serotypes of S. suis are known, the prevalence of serotype 2 being the highest. In the Netherlands, however, serotype 9 is isolated more often (58%) than serotype 2 (28%) from diseased pigs. (Staats et al. 1997) Symptoms caused by S. suis serotype 9 are mostly seen in weaned pigs. (Beineke et al. 2008) They show a reduction in live weight growth, become rough coated and fever may be present. Later on, warm and swollen joints can be observed. Stiffness may occur and the piglets can appear blind or show muscular tremors that can pass into ataxia and eventually death. (Taylor, 2006) The transmission of S. suis is a complicated matter. Especially the transmission of S. suis serotype 9 is much underexposed, but it will presumably show a lot of analogies with serotype 2. The most important routes of transmission of S. suis are hardly investigated, as a result of which unambiguous answers are not available. However, almost every pig is carrier of S. suis, but symptoms mainly occur when pigs are mingled, and come in direct contact with other pigs. 
The current preferred treatment for S. suis is a curative treatment consisting of parenteral administration of antibiotics (ampicillin) and supportive care like painkillers and anti inflammatory drugs. Antibiotics are also often given prophylactic through feed or water. The repeated administration of antibiotics is nevertheless unwanted, because it can elicit antimicrobial resistance. In recent years associations are increasingly made between the discovery of resistant strains of bacteria and the use of antibiotics. (Staats et al. 1997)
To call a halt to these developments it is important to research alternatives to antibiotics.
A possible alternative are phage lysins. Phage lysins are enzymes that can lyse a bacterium’s cell wall. These enzymes are part of a bacteriophage system that is used by bacteriophages to spread, out of the bacterium. Bacteriophages insert their DNA into a bacterium, where it is replicated. Out of these replication products, new phages are assembled. When these new phages are mature they produce the phage lytic enzyme, that can perforate the bacterial cell wall. (Fischetti et al., unpublished results)
These phage lysins are very specific. Each lysin is derived from a specific phage, that attacks a specific bacterial strain. A phage specific to Streptococcus suis was discovered, and with that also two Streptococcus suis-specific lysins became available. These lysins (PlySs1 and PlySs2) were purified and produced at a larger scale using recombinant Escherichia coli bacteria. PlySs1 has proven to be very effective against the 7997 strain of Streptococcus suis in vitro, but high concentrations of lysins were needed to accomplish these effects. (Loeffler et al. 2001, Daniel et al. 2010, Nelson et al. 2001, Fischetti et al., unpublished results)
In recent years lysins have been researched a lot. Lysins have proven to be effective in killing several strains of gram-positive bacteria. However, in case of Streptococcus suis little research has been done in the actual target species: pigs. 








The study population consisted of 22 piglets, which were derived by caesarian section from 3 mixed breed sows. The piglets were deprived of colostrum and raised in five groups in stainless steel isolators. In the isolators a temperature scheme was applied, with the temperature starting at 38°C and ending at 26°C in three weeks. The air flowing into the isolators HEPA filtered and the pressure was kept at a gauge pressure. The piglets were fed slurry and milk with Bacillus subtilis, Bacillus licheniformis and Enterococcus faecium to establish a gut flora.
After 21 days the piglets were placed in a ground pen altogether. At 25 days of age the piglets were divided in two equal groups (n=11) by simple randomization. One group became the untreated control group, the other one the lysin-treated group. Each group was subdivided in a contact (n=6) and inoculated (n=5) group. 
The contact piglets were housed in two different ground pens in different units at 25 days of age. The temperature in these units was kept constant at 26°C, and they were kept under negative pressure. The pigs were fed pelleted feed that was radiated to ensure sterility, from a dry feeder. Fresh water was provided through a nipple drinker.
At 26 days of age the inoculation group was inoculated. Two days later these animals were housed together with the contact piglets in the two units.
A strict hygiene protocol was applied to prevent introduction or transmission of pathogens into or out of the units. At every visit every person that needed to enter the units had to take a shower, put on clean working clothes,  disposable overalls, gloves, a hair net and a mask. When going out of the units, all disposables were discarded. 


Figure 1. Global timeline of the whole experiment.
Inoculum
A colony from the 7997 strain was spread on a colombia culture plate and grown overnight at 37°C and 5% CO2. The next day a 7997 colony from this plate was grown for about 3,5 hours in 2 tubes with 10ml TH until the OD was 0.5. The OD was measured with the Ultrospec10 cell density meter. These tubes were conserved overnight at 4°C. On day 2 the suspension was diluted 1:10 in TH and grown until OD was again 0.5, this took about 1-2 hours. The suspension was centrifuged for 15 minutes at 2000g and 4°C. The pellet was resuspended in 10ml NaCl. This new suspension matched 2-3 108 CFU/ml.
The CFU/ml was checked by spreading 50µl of the 10-5, 10-6 en 10-7 dilutions on a culture plate.
For the inoculation of one piglet 5ml suspension of 2-3 108 CFU/ml was needed. The piglets were inoculated by intranasal dropping of the suspension, while kept under sedation with Stresnil® (azaperone). 
Lysins
The lysins used in this experiment were imported from Rockefeller University in the USA. They were produced in powder form and freeze dried for transport to Utrecht University.
First, PlySs1 and PlySs2 were dissolved in a phosphate buffer. Both lysins were then mixed before administration to the piglets. This mix was run through a 0.22 micron filter to ensure sterility of the suspension.
In total 2.3mg of PlySs1 in 2.6ml 15mM phosphate buffer and 4.94mg PlySs2 in 3.8ml 15 mM phosphate buffers was administrated per piglet. Piglets in the control group were treated with only 6.4ml of the 15mM phosphate buffer.
Half of the fluid (3.2ml) was dropped in the nose of the piglets, whilst the other 3.2ml was applied in the mouth, which was held open with a dental gag to ensure that the fluid ran down the piglets’ nose and throat.
Treatment was conducted on day 0-4 and 11-12 in the contact group, whereas the inoculated piglets were treated on day 2-4 and 11-12. (See also figure 2.)
Saliva swabs
A 3.5 to 4 hours pause was inserted between sampling and treatment, to ensure that sampling did not take place before the lysins were fully functional.
Saliva swabs were taken in the pen by opening the piglet’s mouth with a dental gag and a swab was rotated under the tongue for 5 seconds on each side of the mouth.
The saliva swabs were placed on a roller apparatus for 10 minutes, rotating at maximum speed.
Dilutions of 10-1 and 10-2 were made out of 100µl of the suspension. From these dilutions and the undiluted suspension 50µl was spread on Colombia SS+KV culture plates with a Drigalsky spatula and grown overnight at 37°C in 5%CO2. The remaining 500µl was frozen at -20ºC for PCR. 
The next day the numbers of colonies morphologically resembling Streptococcus suis per plate were counted for all the dilutions. For every plate a pure culture was made of 3 colonies morphologically resembling Streptococcus suis on a Colombia culture plate. These plates were grown overnight at 37ºC in 5%CO2. 
On day 3 an amylase test (DeVriese et al. 1991) was performed on the colonies morphologically resembling Streptococcus suis. The colonies that tested positive were suspended in 500µl TE buffer and frozen at -20ºC to use for PCR.






DNA isolation with Instagene Matrix
A sample of 200µl was taken and placed in a new eppendorf tube. Both tubes were marked with piglet number, date, day of the experiment, and DNA or ‘remains’. Also 200µl TE buffer and NaCl were taken for negative controls. These samples were centrifuged for 1 minute at 12,000g. After centrifuging the supernatant was removed, and 200µl of Instagene Matrix was added, after which the samples were vortexed shortly. 200µl of Instagene Matrix was put in a new eppendorf tube as negative control. 
The samples were then placed in a heat block at 56°C for 30 minutes. After 30 minutes the samples were vortexed thoroughly for 10 seconds and placed in a second heat block at 100°C for 8 minutes. After these 8 minutes the samples were vortexed again for 10 seconds and then centrifuged for 3 minutes at 12,000g. 
After centrifuging the samples were stored at -20°C.
Polymerase chain reaction
To confirm the presence of Streptococcus suis DNA in the samples a real time PCR was performed using the Bio-Rad iQ™5 Multicolor Real-Time PCR Detection System.
The DNA in the samples was isolated using Instagene Matrix (see up here). 
10 µL template was added in a 96-wells plate to a mix of:
	TaKaRa Premix EX Taq							12.5µl
	Roche Diagnostics LightCycler® 
TaqMan® Master H2O PCR Grade					0.5µl 
	Invitrogen CPSH9F forward primer					0.5µl 
o	5’ CAAAGTTAGTTCAGGAAGGAATAGTCT 3’
	Invitrogen CPSH9rev reverse primer					0.5µl
o	5’ CCGAAGTATCTGGGCTACTG 3’
	Biolegio Cps9H FAM P probe						1.0µl
o	5’FAM-TTCAGATCAAGATGATATTTGGGACT-MGB-BHQ 3’

The initialization step was performed at 95°C for 1 minute. Amplification was performed during 45 cycles, each cycle consisting of a denaturation step at 95°C for 10 seconds, an annealing step at 58°C for 30 seconds, and an elongation step at 72°C for 30 seconds. The final elongation step was performed at 40°C for 1 minute. 
A CT-value of 35 or higher was counted as a negative sample, as well as no CT-value. A CT-value lower than 25 was counted as a positive sample.
Clinical signs








Fever	Rectal body temperature ≥40,0˚C	0	No
		1	Yes
CNS Symptoms	E.g. Blindness, tremors, ataxia	0	No
		3	Yes
Lameness	Grade 1: avoiding movement of leg	0	No
	Grade 2: not bearing weight on leg 	1	Grade 1
		2	Grade 2
Table 1. Clinical Scoring
Statistical methods
Statistical analyses were performed using IBM SPSS 19. Unpaired t-tests were performed to calculate any statistically significant difference in means concerning transmission and total clinical score.
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Table 3. Clinical scoring for the lysin treated group


Figure 3. Total clinical score for both groups.

In figure 4 the total clinical score for the contact pigs (n=6 in both groups) is shown. The total score for the untreated group was 85 points, and the total score for the lysin treated group was 28. An unpaired t-test showed no significant difference between these two groups (P=0.146).

























 Table 5. Results of the PCR test in the lysin treated group

 	Negative test result 
 	Positive test result 
 	Deceased 
•	Clinical symptom(s) observed 


Figure 5. Box plot of the first day pigs tested positive in the PCR test for S. suis serotype 9 in both groups.





The results from the unpaired t-test on the total clinical score show that there is no statistically (P<0,05) significant difference in clinical symptoms between the control group and the group that was treated with lysins (P=0,495). Also, when only the score of the contact piglets in both groups was compared, no statistically significant difference was found (P=0,146). At the same time, there was no statistically significant reduction in transmission in the lysin-treated group (P=0,803). These results, unfortunately, contradict outcomes of other studies on lysins in vitro and in vivo. (Daniel et al. 2010, Loeffler et al. 2003, Nelson et al, 2001.).
Several causes can be suggested to explain these results. First, the dosage of inoculation could have been too high, and therefore the relative concentration of lysins applied became too low. However, this is not a very plausible explanation for the results achieved in the contact pigs because it is likely that the contact pigs were not exposed to such a high dose of bacteria. Secondly, the absolute concentration of lysins may have been insufficient to achieve a satisfactory result. The method of application also deserves some attention. In this experiment the solution was dropped in the nose and throat of the pigs, but maybe the lysins would have a better working action if they were atomized. By just dropping the solution in the  nose the pigs could easily sneeze the fluid out, or swallow it after which the lysins were digested in the stomach.
At present, lysins are not yet suitable for use in practice. The costs of quantity production of lysins are too high, and because of the individual treatment it is too labour-intensive. Because of this, farmers might not be very interested, also because cheaper and easier alternatives are on the market. Moreover, the effectivity of lysins still needs research, because the reduction in transmission has not been proven, yet being the main aim for use in practice. For pig farmers prevention of disease is the most important. For example, testing lysins on sows could be interesting, because in that way S. suis could be exterminated at the source.
However, if lysins may turn out to be effective, a great alternative for antibiotics would arise. Because of the narrow spectrum, and the unique way of acting against bacteria, little resistance against lysins is expected. Also, it is a very fast-acting and safe agent, up to now. (Fischetti, 2010)
It is difficult to extrapolate these results to a field situation, because the piglets used in this research are not quite comparable to piglets in the field. Piglets in the field have had colostrum from the sow and as a result are better protected against Streptococcus suis. Also, these piglets could already become carrier pigs at birth.
A lot of suggestions for further research can be made. For example, if lysins were to be produced on a larger (commercial) scale, exact concentrations would need to be determined, as well as a guaranteed safety in use for man and animal. Besides that, different methods of administration could be worth investigation. A different adjuvant could be used, to ensure that lysins stay on mucous membranes longer. Also atomization of lysins could be tested, or even systemic administration (e.g. intravenous), because Streptococcus suis migrates through the whole body through the bloodstream. A final suggestion would be treating sows with lysins, to tackle the problem at the source. After all, most piglets are infected with Streptococcus suis by their mothers. 
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